TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) disclosed that it repurchased 217,000 H-shares on 24 July 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HKD 10.18 to HKD 10.72, with a volume-weighted average cost of HKD 10.3122 per share, bringing the total consideration to approximately HKD 2.24 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.07% to 311.97 million shares. Treasury shares rose to 718,000, while the total number of issued shares remained unchanged at 312.69 million.

The buyback forms part of the repurchase mandate approved on 18 June 2026, which authorises the company to repurchase up to 31.27 million shares. Cumulative repurchases under this mandate now stand at 718,000 shares, equivalent to 0.23% of the issued shares outstanding at the mandate date.

All 217,000 shares repurchased on 24 July 2026 are being held as treasury shares; no cancellations have been executed. In line with Hong Kong listing rules, TransThera Sciences is subject to a moratorium on issuing new shares or disposing of treasury shares until 23 August 2026.